DOI:
10.1055/s-00000105
Zentralblatt für Gynäkologie
LinksClose Window
References
O'Shaughnessy JA, Blum J, Moiseyenko V. et al.
Randomized, open label, phase II trial of oral capecitabine (xeloda) vs a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer.
Ann Oncol 2001; 12: 1247-1254
Search in:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.